Skip to main content

Table 4 Disease course of multifocal placebo patients by symptoms and by signs after the CIS

From: MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome

  All multifocal Multifocal by symptoms Multifocal by signs p-value*
N 83 50 (60%) 33 (40%)  
CDMS %* over 2 years 44% 49% 37% 0.3554
Median annualized cumulative number of NALs over the study (quartiles) 3.6
(1.0–12.5)
5.3
(1.6–13.4)
2.6
(0–7.0)
0.0424
  1. *Compares multifocal patients by symptoms vs. multifocal patients by signs
  2. Kaplan-Meier estimate at day 720, Log rank test
  3. Wilcoxon test
  4. CDMS: clinically definite MS
  5. NAL: newly active lesion
  6. Gd: gadolinium